Agilent Technologies HaloPlexHS Target Enrichment System

Agilent Technologies has launched the HaloPlex^HS target enrichment system, designed to improve the speed and accuracy of clinical cancer research. The product will enable researchers to rapidly and accurately identify disease-associated variants in tumour samples - information that can be vital to research in cancer treatments.

The amplicon-based targeted sequencing method is based on Agilent’s HaloPlex technology. The method enables clinical researchers to accurately identify low-frequency somatic variants in solid tumours and haematological cancers. It is a sensitive, specific and rapid method for detection of mutations below 1% for tumour burden monitoring.

The target enrichment technology incorporates more than 1 million unique molecular barcodes for accurate detection of alleles at low frequencies. The molecular barcodes are especially important for cancer researchers who work with heterogeneous samples in which driver mutations can be present in subclonal cell populations.